RxDoctor Payments Data

Jeffrey Lapeyrolerie, MD

Urology · Middleburg Hts, OHNPI 1952372260

Payments from drug & device makers

$15,133in general payments, 2019–2025

Across 323 payments — averaging $46.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$4K
  • Coloplast$2K
  • Boston Scientific$1K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$796
  • Olympus America Inc.$637
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$1,69011%
  • Travel & lodging$7835%
  • Food & beverage$12,06080%
  • Education$6004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,133 in reported general payments places this provider in the 80th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$386,722
Medicare patients
714
Services billed
7,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide96$1,448,008
MyrbetriqMirabegron82$56,792
OrgovyxRelugolix17$46,903
GemtesaVibegron32$29,792
Mirabegron ErMirabegron15$12,194
Tamsulosin Hcl634$11,051
Finasteride258$3,983
Bethanechol Chloride33$3,499
Bicalutamide71$3,348
Potassium Citrate ErPotassium Citrate19$1,409
Testosterone Cypionate60$1,248
Cephalexin376$1,188
Oxybutynin Chloride ErOxybutynin Chloride48$857
Alfuzosin Hcl ErAlfuzosin Hcl32$826
Ciprofloxacin Hcl113$598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,044$1,504,800178 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$796$76,69649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 485 urology providers in Ohio.

Other urology in Middleburg Hts

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →